Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

... contact Jason Kantor at Credit Swisse'. Their fund is livid over the "mixed" reporting of FDA on Iclusig. Serious issues have been put forth as to why this occurred.
The FDA needs to be "outed" for this bias so damaging to so many. Only winners here have been the insiders where ever they are, i.e., FDA and/or hedgies. Do the math;..140 MILLION share traded(shorted) at a profit ...

"I really appreciate all the information on the event rates for Iclusig, but there just seems to be a pattern where FDA says one thing and then you guys come on the call publicly and say something else. So I'm just wondering, what's the logic of having this debate in a public forum? It just seems like every time you guys do that, they come down hard on you at the next possible opportunity. So I'm just wondering why you think this should be prosecuted in public rather than just in meetings with FDA?", asked Crédit Suisse analyst Jason Kantor at 3Q CC.

What's the root cause of the debate between the FDA and Ariad?

Ariad insisted on standard criteria while the FDA didn't. Ariad felt obligated to, in a very careful way, explain their understanding of the clinical data because of fears the FDA “created a lot of confusion and questions” among doctors and patients.

As predicted by the pattern Jason Kantor observed, the FDA came down hard on Ariad at the next possible opportunity on October 30, 2013.